Grand Pharmaceutical Group Limited

As of December 31, 2025, Grand Pharmaceutical Group Limited carries a market capitalization of 27.49B, placing it among publicly traded companies globally. Its enterprise value stands at 30.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Grand Pharmaceutical Group Limited's next confirmed earnings release is scheduled for March 17, 2027.

As of December 31, 2025, Grand Pharmaceutical Group Limited has 3.50B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Grand Pharmaceutical Group Limited maintains a current ratio of 1.14, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Grand Pharmaceutical Group Limited's stock has declined approximately 46.15% over the past 52 weeks. The 50-day moving average sits at 4.95, while the 200-day moving average is 6.04.

As of December 31, 2025, Grand Pharmaceutical Group Limited holds 2.07B in cash and equivalents against 4.72B in total debt, resulting in a net debt position of 3.53B. Total book value stands at 17.02B, with working capital of 990.82M providing operational flexibility.

Grand Pharmaceutical Group Limited's most recent stock split took place on July 13, 2018 with a 733:737 split ratio.